By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


SEARCH JOBS

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

Key Statistics


Email: info@medivation.com
Ownership: Public

Web Site: Medivation
Employees: 18
Symbol: MDVN
 





Collaborations

Pfizer 





Company News
Regeneron (REGN) Stock Rocks, but Vertex (VRTX), Medivation (MDVN) & Jazz Pharma (JAZZ) Roll 2/3/2016 6:08:01 AM
Medivation (MDVN) To Present At Leerink Partners 5th Annual Global Healthcare Conference 1/28/2016 10:50:00 AM
Medivation (MDVN) Release: Journal Of Clinical Oncology Publishes Results From The STRIVE Trial Of Enzalutamide Compared To Bicalutamide In Castration-Resistant Prostate Cancer 1/27/2016 10:36:57 AM
Medivation (MDVN) Stock Falls After the FDA Places Partial Clinical Hold on MDV9300 1/26/2016 7:51:45 AM
Life Sciences Executive To Join Patheon (PTI.TO) 1/12/2016 12:25:24 PM
NanoString (NSTG) Enters Into Collaboration Agreement With Medivation (MDVN) And Astellas (ALPMY) To Develop Novel Companion Diagnostic Test 1/11/2016 1:55:41 PM
Medivation (MDVN) To Present At J.P. Morgan Healthcare Conference 1/5/2016 10:48:23 AM
Medivation (MDVN) Initiates Pivotal Clinical Trial Of MDV9300 In Diffuse Large B-Cell Lymphoma 12/21/2015 11:17:25 AM
Medivation (MDVN) Announces Participation At Upcoming Investor Conference 11/10/2015 1:05:36 PM
Medivation (MDVN) Reports Third Quarter 2015 Financial Results 11/9/2015 2:42:55 PM
12345678910...
//-->